{"gene":"ABCD1","run_date":"2026-04-28T17:12:36","timeline":{"discoveries":[{"year":1993,"finding":"The ALD gene was identified by positional cloning; it encodes a putative peroxisomal membrane protein with significant homology to the ATP-binding cassette (ABC) superfamily of transporters, specifically to the 70-kDa peroxisomal membrane protein involved in peroxisome biogenesis.","method":"Positional cloning, cDNA isolation, sequence analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original positional cloning discovery, foundational paper with >1000 citations","pmids":["8441467"],"is_preprint":false},{"year":1994,"finding":"ALDP (the adrenoleukodystrophy protein encoded by ABCD1) is a 75-80 kDa membrane protein localized to the peroxisomal membrane, as demonstrated by immunofluorescence and immunoelectron microscopy; the protein is absent in ALD patients with disease-causing mutations.","method":"Monoclonal antibody generation, Western blotting, immunofluorescence, immunoelectron microscopy","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1–2 — direct subcellular localization by immunoelectron microscopy, replicated by two independent groups (PMID 8004093, 8002973)","pmids":["8004093","8002973"],"is_preprint":false},{"year":1995,"finding":"Missense mutations in ABCD1 can abolish ALDP protein stability or peroxisomal localization; mutations in the carboxy terminus affect protein stabilization, while mutations in the amino-terminal half can still permit some ALDP expression and peroxisomal targeting.","method":"Indirect immunofluorescence of patient fibroblasts correlated with mutation analysis","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2–3 — systematic immunofluorescence in 35 patients correlated with sequenced mutations; single lab but large cohort","pmids":["7668254"],"is_preprint":false},{"year":1996,"finding":"The carboxy terminus of ALDP is required for protein stabilization; frameshift, nonsense, and carboxy-terminal missense mutations result in complete absence of ALDP protein, while amino-terminal missense mutations allow residual ALDP expression.","method":"Western blotting and immunofluorescence in patient fibroblasts correlated with mutation type","journal":"Journal of inherited metabolic disease","confidence":"Medium","confidence_rationale":"Tier 2–3 — systematic protein-level analysis in 24 ALD patients from 17 kindreds","pmids":["8892025"],"is_preprint":false},{"year":1997,"finding":"Knockout of the Abcd1 gene in mice results in reduced peroxisomal beta-oxidation of VLCFAs and significantly elevated saturated VLCFA levels in all tissues, confirming that ABCD1 (not VLCS) is the gene responsible for X-ALD and that it is required for VLCFA beta-oxidation.","method":"Gene targeting (knockout mouse), biochemical beta-oxidation assays, lipid analysis, electron microscopy","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — genetic KO model with biochemical phenotyping, replicated findings; >200 citations","pmids":["9256488"],"is_preprint":false},{"year":1999,"finding":"ALDP forms homodimers with itself and heterodimers with other peroxisomal ABC half-transporters (ALDRP/ABCD2 and PMP70/ABCD3); two X-ALD disease mutations in the carboxy-terminal half disrupt both homo- and heterodimerization, suggesting that loss of ALDP dimerization contributes to X-ALD pathogenesis.","method":"Yeast two-hybrid system, co-immunoprecipitation","journal":"Neurochemical research","confidence":"Medium","confidence_rationale":"Tier 3 — yeast two-hybrid plus co-IP; single lab but consistent across two methods","pmids":["10227685"],"is_preprint":false},{"year":1999,"finding":"ALDP overexpression by itself restores peroxisomal VLCFA beta-oxidation in SV40T-transformed cells (which have reduced ALDP and impaired VLCFA oxidation), demonstrating that ALDP is a fundamental, rate-limiting component of peroxisomal VLCFA beta-oxidation and may act as a 'gatekeeper' for VLCFA homeostasis.","method":"ALDP overexpression in SV40T-transformed fibroblasts, peroxisomal beta-oxidation assay","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — functional rescue experiment with defined biochemical readout","pmids":["10068511"],"is_preprint":false},{"year":1999,"finding":"ALDP homo- and heterodimerizes with peroxisomal ABC half-transporters ALDRP and PMP70; two ALD disease mutations in the C-terminal half abolish both homo- and heterodimerization as demonstrated by yeast two-hybrid and co-immunoprecipitation.","method":"Yeast two-hybrid, co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 — two independent methods, disease mutations tested; single lab","pmids":["10551832"],"is_preprint":false},{"year":2001,"finding":"Deletion of the ABCD1 ATG translation initiation codon results in expression of an N-terminally truncated ALDP (missing first 65 amino acids) via internal translation initiation; this truncated protein is correctly trafficked to peroxisomes but reduces VLCFA beta-oxidation to ~20% of normal and uniformly causes AMN phenotype in the affected family.","method":"Genomic sequencing, RT-PCR, Western blotting, immunofluorescence, in vitro VLCFA beta-oxidation assay","journal":"Neurology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods in single lab; functional assay directly linking truncated protein to reduced beta-oxidation","pmids":["11739809"],"is_preprint":false},{"year":2003,"finding":"ALDP facilitates the functional interaction between peroxisomes and mitochondria; in ALD mouse tissues, peroxisomal VLCFA beta-oxidation is normal despite elevated VLCFA levels, suggesting that ALDP's primary role involves coordinating peroxisome-mitochondria cross-talk rather than directly determining beta-oxidation rate, and mitochondrial structural abnormalities were found in adrenal cortical cells of ALD mice.","method":"ALD mouse tissue beta-oxidation assays, pharmacological VLCFA reduction, electron microscopy of adrenal cells","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple assays in mouse model; challenges simple transport model with mechanistic alternative","pmids":["12509471"],"is_preprint":false},{"year":2004,"finding":"In vivo, mouse liver ALDP forms predominantly homomeric complexes; no evidence of heteromeric interactions with PMP70 or accessory proteins was found under normal expression conditions, indicating homomers are the predominant functional units.","method":"Two-step purification of PMP70 complex, preparative immunoprecipitation of ALDP complex from mouse liver, protein identification","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — purification to apparent homogeneity plus immunoprecipitation; single lab but rigorous approach","pmids":["15276650"],"is_preprint":false},{"year":2008,"finding":"Human ABCD1 (ALDP) functions as a homodimer and is involved in the transport of acyl-CoA esters across the peroxisomal membrane; expression of human ABCD1 cDNA alone rescued the pxa1/pxa2Δ yeast mutant phenotype, and tandem-MS analysis of intracellular acyl-CoA esters demonstrated that the Pxa1p/Pxa2p heterodimer (and by extension ABCD1 homodimer) transports a spectrum of acyl-CoA esters.","method":"Yeast complementation assay, tandem-MS quantification of intracellular acyl-CoA esters","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1–2 — functional reconstitution in yeast with mass spectrometry substrate identification; >180 citations","pmids":["18757502"],"is_preprint":false},{"year":2008,"finding":"Silencing of Abcd1 (ALDP) and Abcd2 (ALDRP) genes in mouse primary astrocytes causes VLCFA accumulation and triggers an inflammatory response mediated by transcription factors NF-κB, AP-1, and C/EBP; correction of the metabolic defect with monoenoic fatty acids reduced inducible nitric oxide synthase and inflammatory cytokine expression, directly linking VLCFA accumulation to inflammation.","method":"siRNA-mediated gene silencing in primary astrocytes, cytokine measurement, transcription factor analysis, monoenoic FA rescue experiment","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA KD with rescue experiment; mechanistic pathway placement via NF-κB/AP-1/C/EBP","pmids":["18723473"],"is_preprint":false},{"year":2010,"finding":"Human ABCD1 and ABCD2 have distinct substrate specificities for peroxisomal fatty acid beta-oxidation transport; ABCD1 preferentially transports saturated very long-chain fatty acids (C24:0, C26:0), while ABCD2 preferentially transports polyunsaturated VLCFAs (C22:6, C24:6) and C22:0, as determined by fatty acid oxidation studies in pxa1/pxa2Δ yeast expressing each human transporter.","method":"Yeast complementation assay with individual human ABCD1 or ABCD2 cDNAs, fatty acid beta-oxidation studies with specific substrates","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1–2 — functional reconstitution in yeast with systematic substrate specificity profiling; >100 citations","pmids":["21145416"],"is_preprint":false},{"year":2013,"finding":"The peroxisomal beta-oxidation defect in X-ALD is directly caused by ABCD1 dysfunction: blocking ABCD1 with a specific antibody in control fibroblasts reduced beta-oxidation to X-ALD levels; C26:0-CoA esters are transported by ABCD1 independently of additional CoA synthetase activity, and residual beta-oxidation of C26:0-CoA in X-ALD fibroblasts is mediated by ABCD3.","method":"Primary human fibroblast beta-oxidation assays, specific antibody blocking of ABCD1, mRNA/protein quantification, isolated peroxisome assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — antibody-blocking functional assay in human cells with multiple orthogonal approaches; >100 citations","pmids":["23671276"],"is_preprint":false},{"year":2015,"finding":"Silencing of ABCD1 in human brain microvascular endothelial cells causes downregulation of the transcription factor c-MYC, which in turn decreases tight junction protein CLDN5 and increases adhesion molecule ICAM1, leading to greater monocyte adhesion and transmigration; MYC silencing alone mimics ABCD1 silencing effects on endothelial barrier function.","method":"siRNA silencing of ABCD1 in human brain microvascular endothelial cells, PCR array, MYC silencing epistasis experiment, monocyte transmigration assay","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2 — KD with pathway placement via epistasis (MYC silencing phenocopy); single lab but multiple methods","pmids":["26377633"],"is_preprint":false},{"year":2015,"finding":"ABCD1 deletion in oligodendrocytes and astrocytes causes mitochondrial structural and functional perturbations including reduced electron transport chain enzyme activities, reduced TCA cycle activity, dysregulated mitochondrial redox status, and disrupted membrane potential; these mitochondrial defects are corrected by the HDAC inhibitor SAHA.","method":"siRNA silencing of ABCD1 in B12 oligodendrocytes and U87 astrocytes, enzyme activity assays for ETC and TCA cycle, mitochondrial membrane potential measurement, SAHA rescue","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — KD with multiple biochemical readouts and pharmacological rescue; single lab","pmids":["25393703"],"is_preprint":false},{"year":2000,"finding":"PEX19 binds ALDP (ABCD1) and other peroxisomal membrane proteins; PEX19 is predominantly cytoplasmic and is required for peroxisomal membrane protein targeting and insertion, providing the mechanism by which ABCD1 is delivered to the peroxisomal membrane.","method":"Co-immunoprecipitation, mislocalization experiment (nuclear PEX19 leads to nuclear accumulation of PMPs), PMP binding assays","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — functional mislocalization experiment plus binding assays; >250 citations; ABCD1 identified as PEX19 cargo","pmids":["10704444"],"is_preprint":false},{"year":2021,"finding":"Saturated VLCFAs cause ER stress in ALD fibroblasts whereas monounsaturated VLCFAs do not; pharmacological induction of SCD1 (stearoyl-CoA desaturase-1) shifts VLCFA from saturated to monounsaturated forms, reducing VLCFA toxicity; in Abcd1-/y mice, LXR agonist treatment reduces VLCFA levels in ALD-relevant tissues.","method":"Drug screen in zebrafish ALD model, SCD1 pharmacological inhibition/induction in human fibroblasts, CRISPR knockout of scd1 in zebrafish, ER stress assays, Abcd1-/y mouse dietary LXR agonist treatment","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 — multiple model systems with mechanistic ER stress readout; single lab but orthogonal approaches","pmids":["33690217"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structures of human ABCD1 in four distinct conformational states reveal that: two transmembrane domains form the substrate translocation pathway; two nucleotide-binding domains form the ATP-binding/hydrolysis site; C26:0-CoA binds to the TMDs and stimulates ATPase activity; W339 in TM5 is essential for substrate binding and stimulation of ATP hydrolysis; a unique C-terminal coiled-coil domain negatively modulates NBD ATPase activity; the outward-facing state shows ATP-driven NBD dimerization opening the TMDs to the peroxisomal lumen for substrate release.","method":"Cryo-electron microscopy (6 structures in 4 conformational states), ATPase activity assays, mutagenesis of W339","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structures with mutagenesis and functional ATPase assays; provides complete mechanistic framework for ABCD1 transport cycle","pmids":["36810450"],"is_preprint":false}],"current_model":"ABCD1 (ALDP) is a peroxisomal membrane ABC half-transporter that homodimerizes to form a functional unit whose cryo-EM structures reveal a substrate translocation pathway in the transmembrane domains and an ATP-binding/hydrolysis site in the nucleotide-binding domains; C26:0-CoA binds TM5 residue W339 to stimulate ATPase activity, driving translocation of very long-chain fatty acyl-CoA esters from the cytosol into the peroxisome for beta-oxidation, and ABCD1 deficiency directly impairs this transport, causing VLCFA accumulation that triggers ER stress, oxidative stress, mitochondrial dysfunction, NF-κB/AP-1-mediated neuroinflammation, and c-MYC-dependent blood-brain barrier disruption."},"narrative":{"teleology":[{"year":1993,"claim":"Positional cloning identified the gene mutated in X-linked adrenoleukodystrophy, revealing it encodes a peroxisomal ABC transporter homolog and thereby establishing the molecular basis of ALD.","evidence":"Positional cloning and cDNA sequence analysis from ALD patient DNA","pmids":["8441467"],"confidence":"High","gaps":["No biochemical function or substrate identified at this stage","Protein localization inferred from homology, not directly demonstrated"]},{"year":1994,"claim":"Direct visualization of ALDP at the peroxisomal membrane confirmed the predicted subcellular localization and showed the protein is absent in ALD patients, linking loss of a peroxisomal transporter to disease.","evidence":"Immunoelectron microscopy and immunofluorescence with monoclonal antibodies in normal and ALD patient fibroblasts","pmids":["8004093","8002973"],"confidence":"High","gaps":["No transport activity demonstrated","Mechanism of peroxisomal targeting unknown"]},{"year":1997,"claim":"Abcd1 knockout mice recapitulated VLCFA accumulation with impaired peroxisomal β-oxidation, establishing that ABCD1 is required in vivo for VLCFA catabolism.","evidence":"Gene-targeted knockout mouse with biochemical β-oxidation assays and tissue lipid analysis","pmids":["9256488"],"confidence":"High","gaps":["Whether ABCD1 directly transports VLCFAs or acts indirectly remained unresolved","Mouse model lacked overt demyelination"]},{"year":1999,"claim":"Demonstration that ALDP forms homodimers and heterodimers with ABCD2/ABCD3, and that disease mutations disrupt dimerization, established that the functional transporter is a dimer and that dimerization loss contributes to X-ALD.","evidence":"Yeast two-hybrid and co-immunoprecipitation with wild-type and mutant ALDP constructs","pmids":["10227685","10551832"],"confidence":"Medium","gaps":["In vivo stoichiometry of homo- vs. heterodimers not determined","No structural information on the dimer interface"]},{"year":2000,"claim":"Identification of PEX19 as the cytosolic receptor that binds and delivers ABCD1 to the peroxisomal membrane explained how ALDP reaches its site of action.","evidence":"Co-immunoprecipitation and nuclear mislocalization experiment redirecting PEX19-dependent cargoes","pmids":["10704444"],"confidence":"Medium","gaps":["Mechanism of membrane insertion after PEX19 delivery not resolved","Whether PEX19 binding is rate-limiting for ABCD1 biogenesis unknown"]},{"year":2004,"claim":"In vivo purification from mouse liver showed ABCD1 exists predominantly as homodimers under physiological conditions, resolving ambiguity about the native oligomeric state.","evidence":"Two-step purification and immunoprecipitation of endogenous ABCD1 complex from mouse liver","pmids":["15276650"],"confidence":"Medium","gaps":["Liver-specific result; whether homodimers predominate in brain was untested","Single tissue examined"]},{"year":2008,"claim":"Functional reconstitution of human ABCD1 in yeast demonstrated that the homodimer directly transports acyl-CoA esters across the peroxisomal membrane, definitively establishing ABCD1 as a fatty acyl-CoA transporter.","evidence":"Rescue of yeast pxa1/pxa2Δ mutant by human ABCD1 cDNA with tandem-MS quantification of intracellular acyl-CoA esters","pmids":["18757502"],"confidence":"High","gaps":["Substrate specificity for individual VLCFA-CoA species not yet profiled","Whether CoA moiety is transported intact or cleaved was debated"]},{"year":2008,"claim":"ABCD1 silencing in astrocytes revealed that VLCFA accumulation directly activates NF-κB and AP-1 to drive neuroinflammation, providing a mechanistic link between the metabolic defect and inflammatory demyelination in X-ALD.","evidence":"siRNA knockdown of Abcd1/Abcd2 in primary mouse astrocytes with cytokine measurement and monoenoic fatty acid rescue","pmids":["18723473"],"confidence":"Medium","gaps":["In vivo validation of NF-κB/AP-1 pathway in ALD brain not provided","Relative contributions of astrocytes vs. other cell types to inflammation unclear"]},{"year":2010,"claim":"Systematic substrate profiling showed ABCD1 preferentially transports saturated VLCFAs (C24:0, C26:0) whereas ABCD2 prefers polyunsaturated species, explaining the non-redundancy of peroxisomal ABC transporters.","evidence":"Yeast complementation with individual human ABCD1 or ABCD2 cDNAs and substrate-specific β-oxidation assays","pmids":["21145416"],"confidence":"High","gaps":["Structural basis for substrate selectivity unknown","In vivo validation of specificity in mammalian cells incomplete"]},{"year":2013,"claim":"Antibody-blocking experiments in human fibroblasts proved that ABCD1 directly transports C26:0-CoA into peroxisomes and that residual β-oxidation in X-ALD cells depends on ABCD3, establishing the direct transport model and identifying compensatory pathways.","evidence":"ABCD1-specific antibody blocking in control fibroblasts reducing β-oxidation to X-ALD levels; isolated peroxisome assay","pmids":["23671276"],"confidence":"High","gaps":["Whether CoA is hydrolyzed during translocation remained unresolved","ABCD3 compensation not shown to be therapeutically sufficient"]},{"year":2015,"claim":"ABCD1 loss in brain endothelial cells was shown to downregulate c-MYC, reducing tight junction protein CLDN5 and increasing ICAM1-mediated monocyte transmigration, revealing a cell-autonomous mechanism for blood–brain barrier breakdown in cerebral ALD.","evidence":"siRNA knockdown of ABCD1 in human brain microvascular endothelial cells with MYC epistasis and monocyte transmigration assay","pmids":["26377633"],"confidence":"Medium","gaps":["In vivo BBB disruption mechanism not confirmed in animal model","How VLCFA accumulation leads to c-MYC downregulation not defined"]},{"year":2015,"claim":"ABCD1 deficiency was found to cause mitochondrial dysfunction including reduced ETC activity, TCA cycle impairment, and redox dysregulation, revealing that peroxisomal VLCFA transport failure has direct mitochondrial consequences.","evidence":"siRNA silencing of ABCD1 in oligodendrocytes and astrocytes with enzyme activity assays and SAHA rescue","pmids":["25393703"],"confidence":"Medium","gaps":["Molecular mechanism linking VLCFA excess to mitochondrial ETC dysfunction not delineated","SAHA rescue could act through off-target HDAC inhibition effects"]},{"year":2021,"claim":"Saturated VLCFAs were identified as the toxic species causing ER stress in ALD cells, while monounsaturated VLCFAs are non-toxic; pharmacological induction of desaturase SCD1 or LXR agonism reduces VLCFA toxicity, connecting saturation state to pathogenic mechanism.","evidence":"Drug screen in zebrafish ALD model, SCD1 manipulation in human fibroblasts, ER stress assays, Abcd1-/y mouse treatment","pmids":["33690217"],"confidence":"Medium","gaps":["Clinical translatability of SCD1 induction or LXR agonism not established","Whether ER stress is the primary driver vs. a secondary consequence is unclear"]},{"year":2023,"claim":"Cryo-EM structures of ABCD1 in four conformational states resolved the complete transport cycle: C26:0-CoA binds W339 in TM5 to stimulate ATPase activity, ATP-driven NBD dimerization opens TMDs to the peroxisomal lumen, and a C-terminal coiled-coil negatively regulates ATPase activity.","evidence":"Cryo-EM (six structures in four states), ATPase activity assays, W339 mutagenesis","pmids":["36810450"],"confidence":"High","gaps":["Fate of the CoA moiety during translocation not resolved structurally","Structures obtained in detergent micelles; behavior in native peroxisomal membrane may differ","Structural basis for disease-causing missense mutations beyond W339 not systematically mapped"]},{"year":null,"claim":"Major open questions include the structural and biochemical basis by which VLCFA accumulation triggers ER stress, mitochondrial dysfunction, and inflammatory signaling; whether the CoA moiety is cleaved during translocation; and what determines the phenotypic variability between cerebral ALD and AMN in patients with similar mutations.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of ABCD1 in native peroxisomal membrane","Genotype-phenotype modifier genes for cerebral ALD vs. AMN not identified mechanistically","Quantitative transport kinetics for individual VLCFA-CoA species not measured in reconstituted system"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[11,19]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[11,13,14,19]}],"localization":[{"term_id":"GO:0005777","term_label":"peroxisome","supporting_discovery_ids":[1,2,17]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[4,11,13,14]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[11,14,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,4,12,15]}],"complexes":["ABCD1 homodimer"],"partners":["ABCD2","ABCD3","PEX19"],"other_free_text":[]},"mechanistic_narrative":"ABCD1 is a peroxisomal membrane ABC half-transporter that homodimerizes to form a functional transporter importing very long-chain fatty acyl-CoA esters (preferentially saturated C24:0 and C26:0) from the cytosol into the peroxisome for β-oxidation [PMID:18757502, PMID:21145416, PMID:23671276]. Cryo-EM structures reveal that C26:0-CoA binds TM5 residue W339 to stimulate ATPase-driven translocation through the transmembrane domains, with a C-terminal coiled-coil domain negatively modulating NBD activity [PMID:36810450]. Loss-of-function mutations cause X-linked adrenoleukodystrophy (X-ALD) through VLCFA accumulation that triggers ER stress, mitochondrial dysfunction, NF-κB/AP-1-mediated neuroinflammation, and c-MYC-dependent blood–brain barrier disruption [PMID:8441467, PMID:9256488, PMID:33690217, PMID:18723473, PMID:26377633, PMID:25393703]. PEX19 mediates ABCD1 targeting to the peroxisomal membrane [PMID:10704444]."},"prefetch_data":{"uniprot":{"accession":"P33897","full_name":"ATP-binding cassette sub-family D member 1","aliases":["Adrenoleukodystrophy protein","ALDP"],"length_aa":745,"mass_kda":82.9,"function":"ATP-dependent transporter of the ATP-binding cassette (ABC) family involved in the transport of very long chain fatty acid (VLCFA)-CoA from the cytosol to the peroxisome lumen (PubMed:11248239, PubMed:15682271, PubMed:16946495, PubMed:18757502, PubMed:21145416, PubMed:23671276, PubMed:29397936, PubMed:33500543). Coupled to the ATP-dependent transporter activity also has a fatty acyl-CoA thioesterase activity (ACOT) and hydrolyzes VLCFA-CoA into VLCFA prior their ATP-dependent transport into peroxisomes, the ACOT activity is essential during this transport process (PubMed:29397936, PubMed:33500543). Thus, plays a role in regulation of VLCFAs and energy metabolism namely, in the degradation and biosynthesis of fatty acids by beta-oxidation, mitochondrial function and microsomal fatty acid elongation (PubMed:21145416, PubMed:23671276). Involved in several processes; namely, controls the active myelination phase by negatively regulating the microsomal fatty acid elongation activity and may also play a role in axon and myelin maintenance. Also controls the cellular response to oxidative stress by regulating mitochondrial functions such as mitochondrial oxidative phosphorylation and depolarization. And finally controls the inflammatory response by positively regulating peroxisomal beta-oxidation of VLCFAs (By similarity)","subcellular_location":"Peroxisome membrane; Mitochondrion membrane; Lysosome membrane; Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/P33897/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ABCD1","classification":"Not Classified","n_dependent_lines":49,"n_total_lines":1208,"dependency_fraction":0.04056291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ABCD1","total_profiled":1310},"omim":[{"mim_id":"618863","title":"RETINAL DYSTROPHY WITH LEUKODYSTROPHY; RDLKD","url":"https://www.omim.org/entry/618863"},{"mim_id":"616618","title":"ACYL-CoA-BINDING DOMAIN-CONTAINING PROTEIN 5; ACBD5","url":"https://www.omim.org/entry/616618"},{"mim_id":"614362","title":"ACYL-CoA SYNTHETASE, BUBBLEGUM FAMILY, MEMBER 1; ACSBG1","url":"https://www.omim.org/entry/614362"},{"mim_id":"603247","title":"SOLUTE CARRIER FAMILY 27 (FATTY ACID TRANSPORTER), MEMBER 2; SLC27A2","url":"https://www.omim.org/entry/603247"},{"mim_id":"603214","title":"ATP-BINDING CASSETTE, SUBFAMILY D, MEMBER 4; ABCD4","url":"https://www.omim.org/entry/603214"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ABCD1"},"hgnc":{"alias_symbol":["AMN","ALDP","adrenoleukodystrophy"],"prev_symbol":["ALD"]},"alphafold":{"accession":"P33897","domains":[{"cath_id":"-","chopping":"87-238_408-436","consensus_level":"medium","plddt":88.9138,"start":87,"end":436},{"cath_id":"3.40.50.300","chopping":"467-685","consensus_level":"high","plddt":91.6078,"start":467,"end":685},{"cath_id":"1.10.287","chopping":"240-355","consensus_level":"medium","plddt":86.0309,"start":240,"end":355}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P33897","model_url":"https://alphafold.ebi.ac.uk/files/AF-P33897-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P33897-F1-predicted_aligned_error_v6.png","plddt_mean":80.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ABCD1","jax_strain_url":"https://www.jax.org/strain/search?query=ABCD1"},"sequence":{"accession":"P33897","fasta_url":"https://rest.uniprot.org/uniprotkb/P33897.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P33897/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P33897"}},"corpus_meta":[{"pmid":"22889154","id":"PMC_22889154","title":"X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management.","date":"2012","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22889154","citation_count":411,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17342190","id":"PMC_17342190","title":"X-linked adrenoleukodystrophy.","date":"2007","source":"Nature clinical practice. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17342190","citation_count":267,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12065405","id":"PMC_12065405","title":"Control of germination and lipid mobilization by COMATOSE, the Arabidopsis homologue of human ALDP.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12065405","citation_count":231,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8004093","id":"PMC_8004093","title":"The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein.","date":"1994","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8004093","citation_count":229,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9256488","id":"PMC_9256488","title":"A mouse model for X-linked adrenoleukodystrophy.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9256488","citation_count":228,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11748843","id":"PMC_11748843","title":"ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations.","date":"2001","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/11748843","citation_count":226,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22483867","id":"PMC_22483867","title":"X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22483867","citation_count":205,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27312864","id":"PMC_27312864","title":"Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history.","date":"2016","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27312864","citation_count":195,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18757502","id":"PMC_18757502","title":"The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters.","date":"2008","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/18757502","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24316281","id":"PMC_24316281","title":"Pathophysiology of X-linked adrenoleukodystrophy.","date":"2013","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/24316281","citation_count":165,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10227685","id":"PMC_10227685","title":"X-linked adrenoleukodystrophy: genes, mutations, and phenotypes.","date":"1999","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/10227685","citation_count":147,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16949688","id":"PMC_16949688","title":"X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16949688","citation_count":146,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31909500","id":"PMC_31909500","title":"X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies.","date":"2020","source":"International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31909500","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25115486","id":"PMC_25115486","title":"X-linked adrenoleukodystrophy: pathogenesis and treatment.","date":"2014","source":"Current neurology and neuroscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/25115486","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9221959","id":"PMC_9221959","title":"X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.","date":"1997","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/9221959","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7668254","id":"PMC_7668254","title":"Altered expression of ALDP in X-linked adrenoleukodystrophy.","date":"1995","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7668254","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20626745","id":"PMC_20626745","title":"Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis.","date":"2010","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/20626745","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7825602","id":"PMC_7825602","title":"Spectrum of mutations in the gene encoding the adrenoleukodystrophy protein.","date":"1995","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7825602","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20626743","id":"PMC_20626743","title":"General aspects and neuropathology of X-linked adrenoleukodystrophy.","date":"2010","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/20626743","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10088993","id":"PMC_10088993","title":"The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder.","date":"1999","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/10088993","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39383458","id":"PMC_39383458","title":"Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy.","date":"2024","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39383458","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20626744","id":"PMC_20626744","title":"Biochemical aspects of X-linked adrenoleukodystrophy.","date":"2010","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/20626744","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31467997","id":"PMC_31467997","title":"Newborn Screening for X-Linked Adrenoleukodystrophy.","date":"2016","source":"International journal of neonatal screening","url":"https://pubmed.ncbi.nlm.nih.gov/31467997","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26377633","id":"PMC_26377633","title":"Brain endothelial dysfunction in cerebral adrenoleukodystrophy.","date":"2015","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26377633","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10516293","id":"PMC_10516293","title":"Developmental expression of an amn(+) transgene rescues the mutant memory defect of amnesiac adults.","date":"1999","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10516293","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33409397","id":"PMC_33409397","title":"Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD).","date":"2021","source":"Translational gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/33409397","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26073123","id":"PMC_26073123","title":"Oxidative stress, mitochondrial and proteostasis malfunction in adrenoleukodystrophy: A paradigm for axonal degeneration.","date":"2015","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26073123","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39383459","id":"PMC_39383459","title":"Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy.","date":"2024","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39383459","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8566952","id":"PMC_8566952","title":"Identification of mutations in the ALD-gene of 20 families with adrenoleukodystrophy/adrenomyeloneuropathy.","date":"1996","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8566952","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18723473","id":"PMC_18723473","title":"Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/18723473","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29860501","id":"PMC_29860501","title":"Impaired plasticity of macrophages in X-linked adrenoleukodystrophy.","date":"2018","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29860501","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32364223","id":"PMC_32364223","title":"The Changing Face of Adrenoleukodystrophy.","date":"2020","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32364223","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17990981","id":"PMC_17990981","title":"Interactions of cubilin with megalin and the product of the amnionless gene (AMN): effect on its stability.","date":"2008","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/17990981","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7593551","id":"PMC_7593551","title":"Tumor necrosis factor-alpha and X-linked adrenoleukodystrophy.","date":"1995","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/7593551","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15167059","id":"PMC_15167059","title":"Progress in X-linked adrenoleukodystrophy.","date":"2004","source":"Current opinion in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15167059","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36107226","id":"PMC_36107226","title":"Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy.","date":"2022","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36107226","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16305618","id":"PMC_16305618","title":"X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes.","date":"2005","source":"Pediatric transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/16305618","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20088845","id":"PMC_20088845","title":"AMN directs endocytosis of the intrinsic factor-vitamin B(12) receptor cubam by engaging ARH or Dab2.","date":"2010","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/20088845","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22112817","id":"PMC_22112817","title":"Adrenoleukodystrophy in female heterozygotes: underrecognized and undertreated.","date":"2011","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22112817","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32231001","id":"PMC_32231001","title":"Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32231001","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15276650","id":"PMC_15276650","title":"Mouse liver PMP70 and ALDP: homomeric interactions prevail in vivo.","date":"2004","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15276650","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35689610","id":"PMC_35689610","title":"Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation.","date":"2022","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/35689610","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7666063","id":"PMC_7666063","title":"Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy.","date":"1995","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/7666063","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16554262","id":"PMC_16554262","title":"Therapy of X-linked adrenoleukodystrophy.","date":"2006","source":"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16554262","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17581114","id":"PMC_17581114","title":"The Arabidopsis ALDP protein homologue COMATOSE is instrumental in peroxisomal acetate metabolism.","date":"2007","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/17581114","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30769094","id":"PMC_30769094","title":"CRISPR/Cas9-mediated knockout of Abcd1 and Abcd2 genes in BV-2 cells: novel microglial models for X-linked Adrenoleukodystrophy.","date":"2019","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/30769094","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21700483","id":"PMC_21700483","title":"X-linked adrenoleukodystrophy: ABCD1 de novo mutations and mosaicism.","date":"2011","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21700483","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27241966","id":"PMC_27241966","title":"Endocrine Dysfunction in X-Linked Adrenoleukodystrophy.","date":"2016","source":"Endocrinology and metabolism clinics of North America","url":"https://pubmed.ncbi.nlm.nih.gov/27241966","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9195223","id":"PMC_9195223","title":"Mutations in the adrenoleukodystrophy gene.","date":"1997","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/9195223","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22508517","id":"PMC_22508517","title":"The inflammatory response in acyl-CoA oxidase 1 deficiency (pseudoneonatal adrenoleukodystrophy).","date":"2012","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22508517","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25393703","id":"PMC_25393703","title":"ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.","date":"2015","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25393703","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33690217","id":"PMC_33690217","title":"Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33690217","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11968085","id":"PMC_11968085","title":"Characterization of breakpoint sequences of five rearrangements in L1CAM and ABCD1 (ALD) genes.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/11968085","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8892025","id":"PMC_8892025","title":"ALDP expression in fibroblasts of patients with X-linked adrenoleukodystrophy.","date":"1996","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/8892025","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39256476","id":"PMC_39256476","title":"Lipidomic biomarkers in plasma correlate with disease severity in adrenoleukodystrophy.","date":"2024","source":"Communications medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39256476","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36256460","id":"PMC_36256460","title":"Sex-specific newborn screening for X-linked adrenoleukodystrophy.","date":"2022","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/36256460","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18759549","id":"PMC_18759549","title":"Therapy of X-linked adrenoleukodystrophy.","date":"2008","source":"Expert review of neurotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18759549","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9553942","id":"PMC_9553942","title":"Clinical and genetic aspects of X-linked adrenoleukodystrophy.","date":"1998","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/9553942","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22280810","id":"PMC_22280810","title":"Preferential expression of mutant ABCD1 allele is common in adrenoleukodystrophy female carriers but unrelated to clinical symptoms.","date":"2012","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22280810","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24597975","id":"PMC_24597975","title":"Genotype-phenotype correlation of contiguous gene deletions of SLC6A8, BCAP31 and ABCD1.","date":"2014","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24597975","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26634687","id":"PMC_26634687","title":"An overview of the genetics, mechanisms and management of NAFLD and ALD.","date":"2015","source":"Clinical medicine (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26634687","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17125847","id":"PMC_17125847","title":"Immunopathogenesis of adrenoleukodystrophy: current understanding.","date":"2006","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/17125847","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16087056","id":"PMC_16087056","title":"ABCD1 gene mutations in Chinese patients with X-linked adrenoleukodystrophy.","date":"2005","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16087056","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39669199","id":"PMC_39669199","title":"Alcohol-related liver disease (ALD): current perspectives on pathogenesis, therapeutic strategies, and animal models.","date":"2024","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39669199","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8507690","id":"PMC_8507690","title":"Adrenoleukodystrophy gene: unexpected homology to a protein involved in peroxisome biogenesis.","date":"1993","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/8507690","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2690948","id":"PMC_2690948","title":"Structure and regulation of the AMP nucleosidase gene (amn) from Escherichia coli.","date":"1989","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2690948","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38034003","id":"PMC_38034003","title":"X-linked adrenoleukodystrophy and primary adrenal insufficiency.","date":"2023","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/38034003","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11739809","id":"PMC_11739809","title":"ABCD1 translation-initiator mutation demonstrates genotype-phenotype correlation for AMN.","date":"2001","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11739809","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28288261","id":"PMC_28288261","title":"Antioxidant Capacity and Superoxide Dismutase Activity in Adrenoleukodystrophy.","date":"2017","source":"JAMA neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28288261","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8520725","id":"PMC_8520725","title":"Adrenoleukodystrophy: molecular genetics, pathology, and Lorenzo's oil.","date":"1995","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/8520725","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29476661","id":"PMC_29476661","title":"Epigenomic signature of adrenoleukodystrophy predicts compromised oligodendrocyte differentiation.","date":"2018","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/29476661","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21750092","id":"PMC_21750092","title":"Luminal expression of cubilin is impaired in Imerslund-Grasbeck syndrome with compound AMN mutations in intron 3 and exon 7.","date":"2011","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/21750092","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18834860","id":"PMC_18834860","title":"X-linked adrenoleukodystrophy phenotype is independent of ABCD2 genotype.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18834860","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29469952","id":"PMC_29469952","title":"Profiling and Imaging of Phospholipids in Brains of Abcd1-Deficient Mice.","date":"2018","source":"Lipids","url":"https://pubmed.ncbi.nlm.nih.gov/29469952","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22911730","id":"PMC_22911730","title":"Bezafibrate for X-linked adrenoleukodystrophy.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22911730","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17532287","id":"PMC_17532287","title":"[X-linked adrenoleukodystrophy].","date":"2007","source":"Annales d'endocrinologie","url":"https://pubmed.ncbi.nlm.nih.gov/17532287","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37979237","id":"PMC_37979237","title":"Newborn screening for adrenoleukodystrophy: International experiences and challenges.","date":"2023","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37979237","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34943935","id":"PMC_34943935","title":"Molecular Biomarkers for Adrenoleukodystrophy: An Unmet Need.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34943935","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29739804","id":"PMC_29739804","title":"Etiology and treatment of adrenoleukodystrophy: new insights from Drosophila.","date":"2018","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/29739804","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32359032","id":"PMC_32359032","title":"Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy.","date":"2020","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32359032","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8002973","id":"PMC_8002973","title":"Adrenoleukodystrophy gene encodes an 80 kDa membrane protein.","date":"1994","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8002973","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36938877","id":"PMC_36938877","title":"Emerging targets for therapy in ALD: Lessons from NASH.","date":"2023","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/36938877","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34192790","id":"PMC_34192790","title":"Imaging in X-Linked Adrenoleukodystrophy.","date":"2021","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/34192790","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34560537","id":"PMC_34560537","title":"Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies.","date":"2021","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/34560537","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34716609","id":"PMC_34716609","title":"ABCD1 and X-linked adrenoleukodystrophy: A disease with a markedly variable phenotype showing conserved neurobiology in animal models.","date":"2021","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/34716609","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32616675","id":"PMC_32616675","title":"Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy.","date":"2020","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32616675","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21164268","id":"PMC_21164268","title":"Adrenoleukodystrophy.","date":"2010","source":"Endocrine development","url":"https://pubmed.ncbi.nlm.nih.gov/21164268","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36810450","id":"PMC_36810450","title":"Structural insights into substrate recognition and translocation of human peroxisomal ABC transporter ALDP.","date":"2023","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36810450","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3468205","id":"PMC_3468205","title":"Familial spinocerebellar degeneration as an expression of adrenoleukodystrophy.","date":"1986","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/3468205","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10068511","id":"PMC_10068511","title":"Peroxisomal very long chain fatty acid beta-oxidation activity is determined by the level of adrenodeukodystrophy protein (ALDP) expression.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10068511","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7551122","id":"PMC_7551122","title":"Adrenoleukodystrophy.","date":"1995","source":"Current opinion in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/7551122","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11810273","id":"PMC_11810273","title":"Characterisation of two mutations in the ABCD1 gene leading to low levels of normal ALDP.","date":"2001","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11810273","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33274015","id":"PMC_33274015","title":"Deciphering the modifiers for phenotypic variability of X-linked adrenoleukodystrophy.","date":"2020","source":"World journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33274015","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38832897","id":"PMC_38832897","title":"Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy.","date":"2024","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38832897","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12175782","id":"PMC_12175782","title":"Molecular characterization of 21 X-ALD Portuguese families: identification of eight novel mutations in the ABCD1 gene.","date":"2002","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12175782","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28493141","id":"PMC_28493141","title":"Therapeutic strategies in adrenoleukodystrophy.","date":"2017","source":"Wiener medizinische Wochenschrift (1946)","url":"https://pubmed.ncbi.nlm.nih.gov/28493141","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35983253","id":"PMC_35983253","title":"ABCD1 Gene Mutations: Mechanisms and Management of Adrenomyeloneuropathy.","date":"2022","source":"The application of clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35983253","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34946879","id":"PMC_34946879","title":"Biochemical Studies in Fibroblasts to Interpret Variants of Unknown Significance in the ABCD1 Gene.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/34946879","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3119941","id":"PMC_3119941","title":"Adrenoleukodystrophy: biochemical procedures in diagnosis, prevention and treatment.","date":"1987","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/3119941","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19497692","id":"PMC_19497692","title":"Early neuropsychological signs of childhood adrenoleukodystrophy (ALD).","date":"2009","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/19497692","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8441467","id":"PMC_8441467","title":"Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8441467","citation_count":1003,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15772651","id":"PMC_15772651","title":"The DNA sequence of the human X chromosome.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15772651","citation_count":816,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16756494","id":"PMC_16756494","title":"Biochemistry of mammalian peroxisomes revisited.","date":"2006","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16756494","citation_count":761,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22810586","id":"PMC_22810586","title":"Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22810586","citation_count":319,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27342126","id":"PMC_27342126","title":"Identification of Zika Virus and Dengue Virus Dependency Factors using Functional Genomics.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27342126","citation_count":306,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6795626","id":"PMC_6795626","title":"Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells.","date":"1981","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/6795626","citation_count":272,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10704444","id":"PMC_10704444","title":"PEX19 binds multiple peroxisomal membrane proteins, is predominantly cytoplasmic, and is required for peroxisome membrane synthesis.","date":"2000","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10704444","citation_count":259,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6524872","id":"PMC_6524872","title":"Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy.","date":"1984","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/6524872","citation_count":253,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21988832","id":"PMC_21988832","title":"Toward an understanding of the protein interaction network of the human liver.","date":"2011","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21988832","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24480483","id":"PMC_24480483","title":"X-linked adrenoleukodystrophy in women: a cross-sectional cohort study.","date":"2014","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24480483","citation_count":176,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20889312","id":"PMC_20889312","title":"A genome-wide meta-analysis identifies novel loci associated with schizophrenia and bipolar disorder.","date":"2010","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/20889312","citation_count":172,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19204726","id":"PMC_19204726","title":"Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease.","date":"2009","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/19204726","citation_count":170,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31871319","id":"PMC_31871319","title":"Mapping the proximity interaction network of the Rho-family GTPases reveals signalling pathways and regulatory mechanisms.","date":"2019","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31871319","citation_count":137,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29117863","id":"PMC_29117863","title":"RNA-binding activity of TRIM25 is mediated by its PRY/SPRY domain and is required for ubiquitination.","date":"2017","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/29117863","citation_count":135,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23671276","id":"PMC_23671276","title":"Impaired very long-chain acyl-CoA β-oxidation in human X-linked adrenoleukodystrophy fibroblasts is a direct consequence of ABCD1 transporter dysfunction.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23671276","citation_count":115,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10551832","id":"PMC_10551832","title":"Homo- and heterodimerization of peroxisomal ATP-binding cassette half-transporters.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10551832","citation_count":114,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9215666","id":"PMC_9215666","title":"Interchromosomal duplications of the adrenoleukodystrophy locus: a phenomenon of pericentromeric plasticity.","date":"1997","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9215666","citation_count":112,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21145416","id":"PMC_21145416","title":"Differential substrate specificities of human ABCD1 and ABCD2 in peroxisomal fatty acid β-oxidation.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21145416","citation_count":109,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12509471","id":"PMC_12509471","title":"Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12509471","citation_count":108,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7811247","id":"PMC_7811247","title":"X-linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes.","date":"1994","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/7811247","citation_count":106,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30021884","id":"PMC_30021884","title":"Histone Interaction Landscapes Visualized by Crosslinking Mass Spectrometry in Intact Cell Nuclei.","date":"2018","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/30021884","citation_count":101,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46132,"output_tokens":2931,"usd":0.09118},"stage2":{"model":"claude-opus-4-6","input_tokens":6298,"output_tokens":2481,"usd":0.140272},"total_usd":0.547199,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":59368,"output_tokens":5165,"usd":0.12779},"round2_rules_fired":"R2","round2_stage2":{"model":"claude-opus-4-6","input_tokens":8546,"output_tokens":3303,"usd":0.187957}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"Positional cloning identified the ALD gene, whose predicted protein (ALDP) shows significant homology to the 70-kDa peroxisomal membrane protein involved in peroxisome biogenesis and belongs to the ATP-binding cassette superfamily of transporters, suggesting ALDP is a putative peroxisomal transporter molecule.\",\n      \"method\": \"Positional cloning, sequence homology analysis\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original positional cloning discovery, foundational paper replicated across many subsequent studies\",\n      \"pmids\": [\"8507690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ALDP is a peroxisomal membrane protein (~75-80 kDa); immunofluorescence and immunoelectron microscopy localized it to the peroxisomal membrane, and it was absent in cells from ALD patients.\",\n      \"method\": \"Immunofluorescence, immunoelectron microscopy, Western blot, antibody raised against C-terminal epitope\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct subcellular localization by multiple independent microscopy methods, replicated by multiple labs\",\n      \"pmids\": [\"8004093\", \"7668254\", \"8002973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ALDP forms homodimers with itself and heterodimers with other peroxisomal ABC proteins (ALDPR, PMP70, PMP70R); cDNA complementation studies suggest peroxisomal ABC proteins have overlapping functions; at least two peroxisomal VLCFA-CoA synthetase (VLCS) activities exist, one ALDP-dependent and one ALDP-independent.\",\n      \"method\": \"Co-immunoprecipitation, cDNA complementation assays, in vitro beta-oxidation assay\",\n      \"journal\": \"Neurochemical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP and functional complementation in single study; homodimerization confirmed by later work\",\n      \"pmids\": [\"10227685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ALDP overexpression by itself restores peroxisomal VLCFA beta-oxidation in SV40T-transformed control and X-ALD cells, demonstrating ALDP is a fundamental and rate-determining component of peroxisomal VLCFA beta-oxidation and may serve as a 'gatekeeper' for VLCFA homeostasis.\",\n      \"method\": \"Overexpression rescue assay, in vitro peroxisomal beta-oxidation assay\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional rescue assay with clear mechanistic readout in single study\",\n      \"pmids\": [\"10068511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A deletion of the ABCD1 ATG translation initiation codon results in expression of an N-terminal truncated ALDP (missing first 65 amino acids) via internal initiation of translation; this truncated protein is correctly trafficked to peroxisomes but reduces VLCFA beta-oxidation to 20% of normal.\",\n      \"method\": \"Direct sequencing of genomic DNA and cDNA, RT-PCR, Western blotting, indirect immunofluorescence, in vitro VLCFA beta-oxidation assay\",\n      \"journal\": \"Neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods in single study establishing domain function and trafficking\",\n      \"pmids\": [\"11739809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Mouse liver ALDP exists predominantly as homomeric complexes; preparative immunoprecipitation and two-step purification showed no evidence for heteromeric interactions with PMP70 or for accessory proteins under normal expression conditions.\",\n      \"method\": \"Preparative immunoprecipitation, protein complex purification\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal immunoprecipitation in native tissue; single lab but rigorous purification approach\",\n      \"pmids\": [\"15276650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Human ABCD1 (ALDP) functions as a homodimer and is involved in transport of acyl-CoA esters across the peroxisomal membrane; expression of human ABCD1 cDNA alone rescues the pxa1/pxa2Δ yeast mutant phenotype, as shown by restoration of intracellular acyl-CoA ester profiles analyzed by tandem-MS.\",\n      \"method\": \"Yeast complementation assay, tandem-MS analysis of intracellular acyl-CoA esters\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional reconstitution in yeast with biochemical readout; orthogonal methods; strongly supported by structural data from 2023\",\n      \"pmids\": [\"18757502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ABCD1 deficiency in brain microvascular endothelial cells causes VLCFA accumulation and leads to upregulation of adhesion molecules and decreased tight junction proteins via downregulation of transcription factor c-MYC, resulting in increased monocyte adhesion and transmigration.\",\n      \"method\": \"siRNA silencing of ABCD1 in human brain microvascular endothelial cells, PCR array, protein expression analysis, monocyte adhesion/transmigration assays\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined molecular pathway (ABCD1→c-MYC→CLDN5/ICAM1) and functional cellular phenotype; single lab\",\n      \"pmids\": [\"26377633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Silencing of ABCD1 in oligodendrocytes and astrocytes produces structural and functional perturbations in mitochondria, including reduced electron transport chain enzyme activities, reduced TCA cycle activity, disrupted mitochondrial membrane potential, and reduced ATP levels, revealing a functional link between peroxisomal ABCD1 and mitochondrial integrity.\",\n      \"method\": \"siRNA knockdown of ABCD1, mitochondrial enzyme activity assays, ATP measurement, mitochondrial membrane potential assay\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with multiple biochemical readouts; single lab with orthogonal assays\",\n      \"pmids\": [\"25393703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CRISPR/Cas9 knockout of Abcd1 alone in BV-2 microglial cells does not cause VLCFA accumulation, but combined Abcd1/Abcd2 double knockout does, demonstrating functional redundancy between ABCD1 and ABCD2 in microglia for VLCFA transport.\",\n      \"method\": \"CRISPR/Cas9 knockout, VLCFA biochemical analysis, electron microscopy, lipid analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic knockout with biochemical readout; single lab\",\n      \"pmids\": [\"30769094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SCD1 (stearoyl-CoA desaturase-1) activity shifts fatty acid saturation status; pharmacological or genetic reduction of SCD1 increases saturated VLCFA accumulation in ALD fibroblasts and mimics motor phenotype in zebrafish ALD model, while SCD1 induction reduces saturated VLCFAs and alleviates ER stress caused by ABCD1 deficiency.\",\n      \"method\": \"Drug screen in zebrafish ALD model, pharmacological SCD1 inhibition, CRISPR knockout of scd1 in zebrafish, LXR agonist treatment in Abcd1-/y mice, VLCFA and phospholipid profiling in human ALD fibroblasts\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal models (zebrafish, mouse, human fibroblasts), genetic and pharmacological interventions, biochemical readouts; single lab but strong evidence\",\n      \"pmids\": [\"33690217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of human ABCD1 in four conformational states reveal: (1) ABCD1 functions as a homodimer with two TMDs forming the substrate translocation pathway and two NBDs forming the ATP-binding/hydrolysis site; (2) C26:0-CoA substrate binds TMDs and stimulates ATPase activity of NBDs; (3) W339 in TM5 is essential for substrate binding and stimulating ATP hydrolysis; (4) a unique C-terminal coiled-coil domain negatively modulates ATPase activity; (5) ATP binding pulls NBDs together and opens TMDs to the peroxisomal lumen for substrate release.\",\n      \"method\": \"Cryo-EM structure determination (six structures in four states), ATPase activity assays, mutagenesis (W339 mutant)\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution cryo-EM structures combined with mutagenesis and enzymatic assays; multiple conformational states define complete transport cycle\",\n      \"pmids\": [\"36810450\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABCD1 (ALDP) is a peroxisomal membrane ABC half-transporter that functions as a homodimer to import very long-chain fatty acyl-CoA esters (≥C22) from the cytosol into the peroxisome for β-oxidation; cryo-EM structures reveal that C26:0-CoA binds the transmembrane domains and stimulates ATPase activity at the nucleotide-binding domains (with W339 in TM5 being essential for substrate-stimulated hydrolysis), ATP binding drives NBD dimerization and opens the TMDs toward the peroxisomal lumen for substrate release, and a unique C-terminal coiled-coil domain negatively modulates ATPase activity; loss of ABCD1 causes saturated VLCFA accumulation leading to ER stress, mitochondrial dysfunction, and—in brain endothelium—disruption of tight junctions and increased monocyte transmigration via c-MYC downregulation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper, then extract mechanistic discoveries from KEPT papers only.\n\n**EXCLUDE list (non-ABCD1 or non-canonical):**\n- Paper [3] (corpus): Arabidopsis COMATOSE - plant ortholog with fundamentally different context (symbol collision/plant)\n- Paper [25] (corpus): Drosophila *amnesiac* gene - completely different gene (symbol collision with AMN)\n- Paper [26] (corpus): NAFLD/ALD = alcoholic liver disease, not ABCD1\n- Paper [33] (corpus): AMN = amnionless gene - different gene\n- Paper [38] (corpus): AMN = amnionless - different gene\n- Paper [40] (corpus): ALD = alcoholic liver disease\n- Paper [41] (corpus): ALDP/PMP70 dimerization in mouse - KEEP (ALDP = ABCD1)\n- Paper [42] (corpus): ALD = alcoholic liver disease\n- Paper [45] (corpus): Arabidopsis COMATOSE - plant\n- Paper [61] (corpus): ALD = alcoholic liver disease\n- Paper [64] (corpus): ALD = alcoholic liver disease\n- Paper [66] (corpus): E. coli *amn* gene (AMP nucleosidase) - completely different\n- Paper [72] (corpus): AMN = amnionless\n- Paper [82] (corpus): ALD = alcoholic liver disease\n- Paper [39] (corpus): KEEP (X-ALD female carriers)\n- Additional [20] (schizophrenia GWAS) - EXCLUDE\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"The ALD gene was identified by positional cloning; it encodes a putative peroxisomal membrane protein with significant homology to the ATP-binding cassette (ABC) superfamily of transporters, specifically to the 70-kDa peroxisomal membrane protein involved in peroxisome biogenesis.\",\n      \"method\": \"Positional cloning, cDNA isolation, sequence analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original positional cloning discovery, foundational paper with >1000 citations\",\n      \"pmids\": [\"8441467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ALDP (the adrenoleukodystrophy protein encoded by ABCD1) is a 75-80 kDa membrane protein localized to the peroxisomal membrane, as demonstrated by immunofluorescence and immunoelectron microscopy; the protein is absent in ALD patients with disease-causing mutations.\",\n      \"method\": \"Monoclonal antibody generation, Western blotting, immunofluorescence, immunoelectron microscopy\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct subcellular localization by immunoelectron microscopy, replicated by two independent groups (PMID 8004093, 8002973)\",\n      \"pmids\": [\"8004093\", \"8002973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Missense mutations in ABCD1 can abolish ALDP protein stability or peroxisomal localization; mutations in the carboxy terminus affect protein stabilization, while mutations in the amino-terminal half can still permit some ALDP expression and peroxisomal targeting.\",\n      \"method\": \"Indirect immunofluorescence of patient fibroblasts correlated with mutation analysis\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — systematic immunofluorescence in 35 patients correlated with sequenced mutations; single lab but large cohort\",\n      \"pmids\": [\"7668254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The carboxy terminus of ALDP is required for protein stabilization; frameshift, nonsense, and carboxy-terminal missense mutations result in complete absence of ALDP protein, while amino-terminal missense mutations allow residual ALDP expression.\",\n      \"method\": \"Western blotting and immunofluorescence in patient fibroblasts correlated with mutation type\",\n      \"journal\": \"Journal of inherited metabolic disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — systematic protein-level analysis in 24 ALD patients from 17 kindreds\",\n      \"pmids\": [\"8892025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Knockout of the Abcd1 gene in mice results in reduced peroxisomal beta-oxidation of VLCFAs and significantly elevated saturated VLCFA levels in all tissues, confirming that ABCD1 (not VLCS) is the gene responsible for X-ALD and that it is required for VLCFA beta-oxidation.\",\n      \"method\": \"Gene targeting (knockout mouse), biochemical beta-oxidation assays, lipid analysis, electron microscopy\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic KO model with biochemical phenotyping, replicated findings; >200 citations\",\n      \"pmids\": [\"9256488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ALDP forms homodimers with itself and heterodimers with other peroxisomal ABC half-transporters (ALDRP/ABCD2 and PMP70/ABCD3); two X-ALD disease mutations in the carboxy-terminal half disrupt both homo- and heterodimerization, suggesting that loss of ALDP dimerization contributes to X-ALD pathogenesis.\",\n      \"method\": \"Yeast two-hybrid system, co-immunoprecipitation\",\n      \"journal\": \"Neurochemical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — yeast two-hybrid plus co-IP; single lab but consistent across two methods\",\n      \"pmids\": [\"10227685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ALDP overexpression by itself restores peroxisomal VLCFA beta-oxidation in SV40T-transformed cells (which have reduced ALDP and impaired VLCFA oxidation), demonstrating that ALDP is a fundamental, rate-limiting component of peroxisomal VLCFA beta-oxidation and may act as a 'gatekeeper' for VLCFA homeostasis.\",\n      \"method\": \"ALDP overexpression in SV40T-transformed fibroblasts, peroxisomal beta-oxidation assay\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional rescue experiment with defined biochemical readout\",\n      \"pmids\": [\"10068511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ALDP homo- and heterodimerizes with peroxisomal ABC half-transporters ALDRP and PMP70; two ALD disease mutations in the C-terminal half abolish both homo- and heterodimerization as demonstrated by yeast two-hybrid and co-immunoprecipitation.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — two independent methods, disease mutations tested; single lab\",\n      \"pmids\": [\"10551832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Deletion of the ABCD1 ATG translation initiation codon results in expression of an N-terminally truncated ALDP (missing first 65 amino acids) via internal translation initiation; this truncated protein is correctly trafficked to peroxisomes but reduces VLCFA beta-oxidation to ~20% of normal and uniformly causes AMN phenotype in the affected family.\",\n      \"method\": \"Genomic sequencing, RT-PCR, Western blotting, immunofluorescence, in vitro VLCFA beta-oxidation assay\",\n      \"journal\": \"Neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in single lab; functional assay directly linking truncated protein to reduced beta-oxidation\",\n      \"pmids\": [\"11739809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ALDP facilitates the functional interaction between peroxisomes and mitochondria; in ALD mouse tissues, peroxisomal VLCFA beta-oxidation is normal despite elevated VLCFA levels, suggesting that ALDP's primary role involves coordinating peroxisome-mitochondria cross-talk rather than directly determining beta-oxidation rate, and mitochondrial structural abnormalities were found in adrenal cortical cells of ALD mice.\",\n      \"method\": \"ALD mouse tissue beta-oxidation assays, pharmacological VLCFA reduction, electron microscopy of adrenal cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple assays in mouse model; challenges simple transport model with mechanistic alternative\",\n      \"pmids\": [\"12509471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In vivo, mouse liver ALDP forms predominantly homomeric complexes; no evidence of heteromeric interactions with PMP70 or accessory proteins was found under normal expression conditions, indicating homomers are the predominant functional units.\",\n      \"method\": \"Two-step purification of PMP70 complex, preparative immunoprecipitation of ALDP complex from mouse liver, protein identification\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — purification to apparent homogeneity plus immunoprecipitation; single lab but rigorous approach\",\n      \"pmids\": [\"15276650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Human ABCD1 (ALDP) functions as a homodimer and is involved in the transport of acyl-CoA esters across the peroxisomal membrane; expression of human ABCD1 cDNA alone rescued the pxa1/pxa2Δ yeast mutant phenotype, and tandem-MS analysis of intracellular acyl-CoA esters demonstrated that the Pxa1p/Pxa2p heterodimer (and by extension ABCD1 homodimer) transports a spectrum of acyl-CoA esters.\",\n      \"method\": \"Yeast complementation assay, tandem-MS quantification of intracellular acyl-CoA esters\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — functional reconstitution in yeast with mass spectrometry substrate identification; >180 citations\",\n      \"pmids\": [\"18757502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Silencing of Abcd1 (ALDP) and Abcd2 (ALDRP) genes in mouse primary astrocytes causes VLCFA accumulation and triggers an inflammatory response mediated by transcription factors NF-κB, AP-1, and C/EBP; correction of the metabolic defect with monoenoic fatty acids reduced inducible nitric oxide synthase and inflammatory cytokine expression, directly linking VLCFA accumulation to inflammation.\",\n      \"method\": \"siRNA-mediated gene silencing in primary astrocytes, cytokine measurement, transcription factor analysis, monoenoic FA rescue experiment\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA KD with rescue experiment; mechanistic pathway placement via NF-κB/AP-1/C/EBP\",\n      \"pmids\": [\"18723473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Human ABCD1 and ABCD2 have distinct substrate specificities for peroxisomal fatty acid beta-oxidation transport; ABCD1 preferentially transports saturated very long-chain fatty acids (C24:0, C26:0), while ABCD2 preferentially transports polyunsaturated VLCFAs (C22:6, C24:6) and C22:0, as determined by fatty acid oxidation studies in pxa1/pxa2Δ yeast expressing each human transporter.\",\n      \"method\": \"Yeast complementation assay with individual human ABCD1 or ABCD2 cDNAs, fatty acid beta-oxidation studies with specific substrates\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — functional reconstitution in yeast with systematic substrate specificity profiling; >100 citations\",\n      \"pmids\": [\"21145416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The peroxisomal beta-oxidation defect in X-ALD is directly caused by ABCD1 dysfunction: blocking ABCD1 with a specific antibody in control fibroblasts reduced beta-oxidation to X-ALD levels; C26:0-CoA esters are transported by ABCD1 independently of additional CoA synthetase activity, and residual beta-oxidation of C26:0-CoA in X-ALD fibroblasts is mediated by ABCD3.\",\n      \"method\": \"Primary human fibroblast beta-oxidation assays, specific antibody blocking of ABCD1, mRNA/protein quantification, isolated peroxisome assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — antibody-blocking functional assay in human cells with multiple orthogonal approaches; >100 citations\",\n      \"pmids\": [\"23671276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Silencing of ABCD1 in human brain microvascular endothelial cells causes downregulation of the transcription factor c-MYC, which in turn decreases tight junction protein CLDN5 and increases adhesion molecule ICAM1, leading to greater monocyte adhesion and transmigration; MYC silencing alone mimics ABCD1 silencing effects on endothelial barrier function.\",\n      \"method\": \"siRNA silencing of ABCD1 in human brain microvascular endothelial cells, PCR array, MYC silencing epistasis experiment, monocyte transmigration assay\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD with pathway placement via epistasis (MYC silencing phenocopy); single lab but multiple methods\",\n      \"pmids\": [\"26377633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ABCD1 deletion in oligodendrocytes and astrocytes causes mitochondrial structural and functional perturbations including reduced electron transport chain enzyme activities, reduced TCA cycle activity, dysregulated mitochondrial redox status, and disrupted membrane potential; these mitochondrial defects are corrected by the HDAC inhibitor SAHA.\",\n      \"method\": \"siRNA silencing of ABCD1 in B12 oligodendrocytes and U87 astrocytes, enzyme activity assays for ETC and TCA cycle, mitochondrial membrane potential measurement, SAHA rescue\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD with multiple biochemical readouts and pharmacological rescue; single lab\",\n      \"pmids\": [\"25393703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PEX19 binds ALDP (ABCD1) and other peroxisomal membrane proteins; PEX19 is predominantly cytoplasmic and is required for peroxisomal membrane protein targeting and insertion, providing the mechanism by which ABCD1 is delivered to the peroxisomal membrane.\",\n      \"method\": \"Co-immunoprecipitation, mislocalization experiment (nuclear PEX19 leads to nuclear accumulation of PMPs), PMP binding assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional mislocalization experiment plus binding assays; >250 citations; ABCD1 identified as PEX19 cargo\",\n      \"pmids\": [\"10704444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Saturated VLCFAs cause ER stress in ALD fibroblasts whereas monounsaturated VLCFAs do not; pharmacological induction of SCD1 (stearoyl-CoA desaturase-1) shifts VLCFA from saturated to monounsaturated forms, reducing VLCFA toxicity; in Abcd1-/y mice, LXR agonist treatment reduces VLCFA levels in ALD-relevant tissues.\",\n      \"method\": \"Drug screen in zebrafish ALD model, SCD1 pharmacological inhibition/induction in human fibroblasts, CRISPR knockout of scd1 in zebrafish, ER stress assays, Abcd1-/y mouse dietary LXR agonist treatment\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple model systems with mechanistic ER stress readout; single lab but orthogonal approaches\",\n      \"pmids\": [\"33690217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of human ABCD1 in four distinct conformational states reveal that: two transmembrane domains form the substrate translocation pathway; two nucleotide-binding domains form the ATP-binding/hydrolysis site; C26:0-CoA binds to the TMDs and stimulates ATPase activity; W339 in TM5 is essential for substrate binding and stimulation of ATP hydrolysis; a unique C-terminal coiled-coil domain negatively modulates NBD ATPase activity; the outward-facing state shows ATP-driven NBD dimerization opening the TMDs to the peroxisomal lumen for substrate release.\",\n      \"method\": \"Cryo-electron microscopy (6 structures in 4 conformational states), ATPase activity assays, mutagenesis of W339\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures with mutagenesis and functional ATPase assays; provides complete mechanistic framework for ABCD1 transport cycle\",\n      \"pmids\": [\"36810450\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABCD1 (ALDP) is a peroxisomal membrane ABC half-transporter that homodimerizes to form a functional unit whose cryo-EM structures reveal a substrate translocation pathway in the transmembrane domains and an ATP-binding/hydrolysis site in the nucleotide-binding domains; C26:0-CoA binds TM5 residue W339 to stimulate ATPase activity, driving translocation of very long-chain fatty acyl-CoA esters from the cytosol into the peroxisome for beta-oxidation, and ABCD1 deficiency directly impairs this transport, causing VLCFA accumulation that triggers ER stress, oxidative stress, mitochondrial dysfunction, NF-κB/AP-1-mediated neuroinflammation, and c-MYC-dependent blood-brain barrier disruption.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ABCD1 (ALDP) is a peroxisomal membrane ABC half-transporter that functions as a homodimer to import very long-chain fatty acyl-CoA esters (≥C22) into the peroxisome for β-oxidation, thereby maintaining cellular VLCFA homeostasis. Cryo-EM structures show that C26:0-CoA binds the transmembrane domains via a critical W339 residue in TM5 to stimulate ATPase activity at the nucleotide-binding domains; ATP binding drives NBD dimerization and opens the TMDs toward the peroxisomal lumen for substrate release, while a unique C-terminal coiled-coil domain negatively modulates ATPase activity [PMID:36810450]. Loss of ABCD1 causes saturated VLCFA accumulation leading to ER stress, mitochondrial dysfunction in oligodendrocytes and astrocytes, and disruption of tight junctions in brain endothelium via c-MYC downregulation [PMID:25393703, PMID:26377633, PMID:33690217]. Mutations in ABCD1 cause X-linked adrenoleukodystrophy, a peroxisomal disorder characterized by defective VLCFA β-oxidation [PMID:8507690, PMID:8004093].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Positional cloning identified ABCD1 as the gene mutated in X-linked adrenoleukodystrophy, establishing it as a member of the ABC transporter superfamily with predicted peroxisomal membrane localization — the first molecular handle on the disease.\",\n      \"evidence\": \"Positional cloning and sequence homology analysis of the ALD locus\",\n      \"pmids\": [\"8507690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No direct evidence of transport function\", \"Subcellular localization not yet confirmed experimentally\", \"Substrate identity unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Direct visualization confirmed ALDP resides in the peroxisomal membrane and is absent in ALD patient cells, linking protein loss to disease and validating the predicted localization.\",\n      \"evidence\": \"Immunofluorescence, immunoelectron microscopy, and Western blot in human fibroblasts\",\n      \"pmids\": [\"8004093\", \"7668254\", \"8002973\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of peroxisomal targeting not defined\", \"Whether ALDP acts as monomer or oligomer unknown\", \"Transport substrate not identified\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Functional studies established that ALDP is a rate-determining component of peroxisomal VLCFA β-oxidation and can form homodimers and heterodimers with other peroxisomal ABC transporters, raising the question of whether homo- or heterodimers are the physiologically relevant unit.\",\n      \"evidence\": \"Co-immunoprecipitation, cDNA complementation, overexpression rescue of β-oxidation in X-ALD cells\",\n      \"pmids\": [\"10227685\", \"10068511\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of homo- vs. heterodimers in vivo unresolved\", \"Direct transport activity not demonstrated\", \"Substrate specificity not defined biochemically\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Biochemical isolation from native mouse liver showed ALDP exists predominantly as homomeric complexes with no detectable heteromeric interaction with PMP70, resolving the oligomerization question in favor of the homodimer as the physiological unit.\",\n      \"evidence\": \"Preparative immunoprecipitation and two-step purification from mouse liver\",\n      \"pmids\": [\"15276650\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-specific heterodimer formation not excluded\", \"Homodimer function not reconstituted in vitro\", \"Single lab study\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Expression of human ABCD1 alone rescued the yeast pxa1/pxa2Δ mutant and normalized acyl-CoA ester profiles, directly demonstrating that the ABCD1 homodimer transports acyl-CoA esters across the peroxisomal membrane.\",\n      \"evidence\": \"Yeast complementation assay with tandem-MS profiling of intracellular acyl-CoA esters\",\n      \"pmids\": [\"18757502\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate selectivity for specific chain lengths not defined\", \"Transport not reconstituted in purified liposome system\", \"Structural basis of transport unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Loss-of-function studies revealed downstream cellular consequences of ABCD1 deficiency beyond lipid accumulation: mitochondrial dysfunction in glia and disrupted blood–brain barrier integrity via c-MYC-dependent tight junction loss in endothelia, linking VLCFA accumulation to disease-relevant cellular pathology.\",\n      \"evidence\": \"siRNA knockdown in oligodendrocytes, astrocytes, and brain microvascular endothelial cells with enzyme activity, ATP, membrane potential, adhesion, and transmigration assays\",\n      \"pmids\": [\"25393703\", \"26377633\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal chain from VLCFA to mitochondrial damage not molecularly defined\", \"c-MYC downregulation mechanism not identified\", \"In vivo validation in ALD mouse models lacking\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"CRISPR knockout demonstrated functional redundancy between ABCD1 and ABCD2 in microglia, explaining why single ABCD1 loss does not always produce VLCFA accumulation in all cell types.\",\n      \"evidence\": \"CRISPR/Cas9 single and double knockout of Abcd1/Abcd2 in BV-2 microglial cells with VLCFA profiling\",\n      \"pmids\": [\"30769094\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Redundancy not mapped across all CNS cell types\", \"Whether ABCD2 compensatory upregulation occurs in human ALD brain unclear\", \"Does not explain phenotypic variability in patients\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"SCD1-mediated desaturation was identified as a modifier of ABCD1 deficiency, showing that the ratio of saturated to unsaturated VLCFAs — not total VLCFAs alone — drives ER stress and pathology, opening a therapeutic axis.\",\n      \"evidence\": \"Drug screen in zebrafish ALD model, CRISPR scd1 knockout, LXR agonist treatment in Abcd1-/y mice, and VLCFA profiling in human ALD fibroblasts\",\n      \"pmids\": [\"33690217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SCD1 modulation translates to human CNS benefit unknown\", \"Mechanism linking saturated VLCFA to ER stress not fully elucidated\", \"Long-term efficacy and safety of SCD1 induction not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cryo-EM structures captured four conformational states of the ABCD1 homodimer, defining the complete transport cycle: substrate (C26:0-CoA) binding at TMDs via W339, ATP-driven NBD closure, luminal gate opening for substrate release, and negative regulation by the C-terminal coiled-coil — the first atomic-level mechanism for a peroxisomal ABC transporter.\",\n      \"evidence\": \"Cryo-EM (six structures), ATPase assays, and W339 mutagenesis\",\n      \"pmids\": [\"36810450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CoA moiety fate during transport not resolved\", \"Structure of disease-associated missense mutants not determined\", \"Lipid membrane composition effects on transport cycle not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The determinants of clinical phenotypic variability in X-ALD — why identical ABCD1 mutations produce demyelinating cerebral ALD in some patients but only adrenomyeloneuropathy in others — remain mechanistically unexplained.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No modifier gene definitively identified for cerebral vs. spinal phenotype\", \"Cell-type-specific compensatory mechanisms (e.g., ABCD2) not mapped in human tissue\", \"Reconstituted transport in liposomes with defined lipid composition not yet achieved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [6, 11]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 3, 6, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005777\", \"supporting_discovery_ids\": [1, 5, 6, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 6, 10, 11]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [6, 11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 7, 8, 10]}\n    ],\n    \"complexes\": [\n      \"ABCD1 homodimer\"\n    ],\n    \"partners\": [\n      \"ABCD2\",\n      \"ABCD3\",\n      \"SCD1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ABCD1 is a peroxisomal membrane ABC half-transporter that homodimerizes to form a functional transporter importing very long-chain fatty acyl-CoA esters (preferentially saturated C24:0 and C26:0) from the cytosol into the peroxisome for β-oxidation [PMID:18757502, PMID:21145416, PMID:23671276]. Cryo-EM structures reveal that C26:0-CoA binds TM5 residue W339 to stimulate ATPase-driven translocation through the transmembrane domains, with a C-terminal coiled-coil domain negatively modulating NBD activity [PMID:36810450]. Loss-of-function mutations cause X-linked adrenoleukodystrophy (X-ALD) through VLCFA accumulation that triggers ER stress, mitochondrial dysfunction, NF-κB/AP-1-mediated neuroinflammation, and c-MYC-dependent blood–brain barrier disruption [PMID:8441467, PMID:9256488, PMID:33690217, PMID:18723473, PMID:26377633, PMID:25393703]. PEX19 mediates ABCD1 targeting to the peroxisomal membrane [PMID:10704444].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Positional cloning identified the gene mutated in X-linked adrenoleukodystrophy, revealing it encodes a peroxisomal ABC transporter homolog and thereby establishing the molecular basis of ALD.\",\n      \"evidence\": \"Positional cloning and cDNA sequence analysis from ALD patient DNA\",\n      \"pmids\": [\"8441467\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No biochemical function or substrate identified at this stage\", \"Protein localization inferred from homology, not directly demonstrated\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Direct visualization of ALDP at the peroxisomal membrane confirmed the predicted subcellular localization and showed the protein is absent in ALD patients, linking loss of a peroxisomal transporter to disease.\",\n      \"evidence\": \"Immunoelectron microscopy and immunofluorescence with monoclonal antibodies in normal and ALD patient fibroblasts\",\n      \"pmids\": [\"8004093\", \"8002973\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No transport activity demonstrated\", \"Mechanism of peroxisomal targeting unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Abcd1 knockout mice recapitulated VLCFA accumulation with impaired peroxisomal β-oxidation, establishing that ABCD1 is required in vivo for VLCFA catabolism.\",\n      \"evidence\": \"Gene-targeted knockout mouse with biochemical β-oxidation assays and tissue lipid analysis\",\n      \"pmids\": [\"9256488\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ABCD1 directly transports VLCFAs or acts indirectly remained unresolved\", \"Mouse model lacked overt demyelination\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstration that ALDP forms homodimers and heterodimers with ABCD2/ABCD3, and that disease mutations disrupt dimerization, established that the functional transporter is a dimer and that dimerization loss contributes to X-ALD.\",\n      \"evidence\": \"Yeast two-hybrid and co-immunoprecipitation with wild-type and mutant ALDP constructs\",\n      \"pmids\": [\"10227685\", \"10551832\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo stoichiometry of homo- vs. heterodimers not determined\", \"No structural information on the dimer interface\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of PEX19 as the cytosolic receptor that binds and delivers ABCD1 to the peroxisomal membrane explained how ALDP reaches its site of action.\",\n      \"evidence\": \"Co-immunoprecipitation and nuclear mislocalization experiment redirecting PEX19-dependent cargoes\",\n      \"pmids\": [\"10704444\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of membrane insertion after PEX19 delivery not resolved\", \"Whether PEX19 binding is rate-limiting for ABCD1 biogenesis unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"In vivo purification from mouse liver showed ABCD1 exists predominantly as homodimers under physiological conditions, resolving ambiguity about the native oligomeric state.\",\n      \"evidence\": \"Two-step purification and immunoprecipitation of endogenous ABCD1 complex from mouse liver\",\n      \"pmids\": [\"15276650\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Liver-specific result; whether homodimers predominate in brain was untested\", \"Single tissue examined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Functional reconstitution of human ABCD1 in yeast demonstrated that the homodimer directly transports acyl-CoA esters across the peroxisomal membrane, definitively establishing ABCD1 as a fatty acyl-CoA transporter.\",\n      \"evidence\": \"Rescue of yeast pxa1/pxa2Δ mutant by human ABCD1 cDNA with tandem-MS quantification of intracellular acyl-CoA esters\",\n      \"pmids\": [\"18757502\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate specificity for individual VLCFA-CoA species not yet profiled\", \"Whether CoA moiety is transported intact or cleaved was debated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"ABCD1 silencing in astrocytes revealed that VLCFA accumulation directly activates NF-κB and AP-1 to drive neuroinflammation, providing a mechanistic link between the metabolic defect and inflammatory demyelination in X-ALD.\",\n      \"evidence\": \"siRNA knockdown of Abcd1/Abcd2 in primary mouse astrocytes with cytokine measurement and monoenoic fatty acid rescue\",\n      \"pmids\": [\"18723473\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo validation of NF-κB/AP-1 pathway in ALD brain not provided\", \"Relative contributions of astrocytes vs. other cell types to inflammation unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Systematic substrate profiling showed ABCD1 preferentially transports saturated VLCFAs (C24:0, C26:0) whereas ABCD2 prefers polyunsaturated species, explaining the non-redundancy of peroxisomal ABC transporters.\",\n      \"evidence\": \"Yeast complementation with individual human ABCD1 or ABCD2 cDNAs and substrate-specific β-oxidation assays\",\n      \"pmids\": [\"21145416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for substrate selectivity unknown\", \"In vivo validation of specificity in mammalian cells incomplete\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Antibody-blocking experiments in human fibroblasts proved that ABCD1 directly transports C26:0-CoA into peroxisomes and that residual β-oxidation in X-ALD cells depends on ABCD3, establishing the direct transport model and identifying compensatory pathways.\",\n      \"evidence\": \"ABCD1-specific antibody blocking in control fibroblasts reducing β-oxidation to X-ALD levels; isolated peroxisome assay\",\n      \"pmids\": [\"23671276\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CoA is hydrolyzed during translocation remained unresolved\", \"ABCD3 compensation not shown to be therapeutically sufficient\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"ABCD1 loss in brain endothelial cells was shown to downregulate c-MYC, reducing tight junction protein CLDN5 and increasing ICAM1-mediated monocyte transmigration, revealing a cell-autonomous mechanism for blood–brain barrier breakdown in cerebral ALD.\",\n      \"evidence\": \"siRNA knockdown of ABCD1 in human brain microvascular endothelial cells with MYC epistasis and monocyte transmigration assay\",\n      \"pmids\": [\"26377633\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo BBB disruption mechanism not confirmed in animal model\", \"How VLCFA accumulation leads to c-MYC downregulation not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"ABCD1 deficiency was found to cause mitochondrial dysfunction including reduced ETC activity, TCA cycle impairment, and redox dysregulation, revealing that peroxisomal VLCFA transport failure has direct mitochondrial consequences.\",\n      \"evidence\": \"siRNA silencing of ABCD1 in oligodendrocytes and astrocytes with enzyme activity assays and SAHA rescue\",\n      \"pmids\": [\"25393703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism linking VLCFA excess to mitochondrial ETC dysfunction not delineated\", \"SAHA rescue could act through off-target HDAC inhibition effects\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Saturated VLCFAs were identified as the toxic species causing ER stress in ALD cells, while monounsaturated VLCFAs are non-toxic; pharmacological induction of desaturase SCD1 or LXR agonism reduces VLCFA toxicity, connecting saturation state to pathogenic mechanism.\",\n      \"evidence\": \"Drug screen in zebrafish ALD model, SCD1 manipulation in human fibroblasts, ER stress assays, Abcd1-/y mouse treatment\",\n      \"pmids\": [\"33690217\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Clinical translatability of SCD1 induction or LXR agonism not established\", \"Whether ER stress is the primary driver vs. a secondary consequence is unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cryo-EM structures of ABCD1 in four conformational states resolved the complete transport cycle: C26:0-CoA binds W339 in TM5 to stimulate ATPase activity, ATP-driven NBD dimerization opens TMDs to the peroxisomal lumen, and a C-terminal coiled-coil negatively regulates ATPase activity.\",\n      \"evidence\": \"Cryo-EM (six structures in four states), ATPase activity assays, W339 mutagenesis\",\n      \"pmids\": [\"36810450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fate of the CoA moiety during translocation not resolved structurally\", \"Structures obtained in detergent micelles; behavior in native peroxisomal membrane may differ\", \"Structural basis for disease-causing missense mutations beyond W339 not systematically mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include the structural and biochemical basis by which VLCFA accumulation triggers ER stress, mitochondrial dysfunction, and inflammatory signaling; whether the CoA moiety is cleaved during translocation; and what determines the phenotypic variability between cerebral ALD and AMN in patients with similar mutations.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of ABCD1 in native peroxisomal membrane\", \"Genotype-phenotype modifier genes for cerebral ALD vs. AMN not identified mechanistically\", \"Quantitative transport kinetics for individual VLCFA-CoA species not measured in reconstituted system\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [11, 19]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [11, 13, 14, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005777\", \"supporting_discovery_ids\": [1, 2, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [4, 11, 13, 14]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [11, 14, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 4, 12, 15]}\n    ],\n    \"complexes\": [\n      \"ABCD1 homodimer\"\n    ],\n    \"partners\": [\n      \"ABCD2\",\n      \"ABCD3\",\n      \"PEX19\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}